All studies
RecruitingPhase II and Phase III (Integrated)Interventional

A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

This clinical trial is looking at a new treatment approach for advanced stomach cancer and cancer of the junction where the stomach joins the food pipe (gastro-oesophageal junction). It focuses on cancers that have high levels of a specific protein called HER2. The trial tests whether adding an experimental drug called evorpacept (also known as ALX148) to standard medicines—including Herceptin, Cyramza, and paclitaxel chemotherapy—can help shrink tumours and help people live longer. Evorpacept works by helping the body's immune system recognise and attack cancer cells. In this trial, some participants receive the new drug combination while others receive standard care. Doctors will closely monitor how well the treatment controls the cancer, whether tumours shrink, and what side effects occur. The trial is open to adults aged 18 and older whose cancer has progressed or spread.

At a glance

Status
Recruiting
Phase
Phase II and Phase III (Integrated)
Sponsor
Alx Oncology Inc.
Enrolment target
87
Start
27 Feb 2024

What is this study about?

This study looks at advanced cancers of the stomach and the gastro-oesophageal junction, which is the area where the food pipe joins the stomach. In some people, these cancer cells produce unusually high amounts of a protein called HER2. HER2 can cause cancer cells to grow and multiply more quickly. While there are already treatments that target HER2, doctors are looking for better ways to keep the cancer under control when standard therapies are no longer working.

The trial is testing a new drug called evorpacept (ALX148). Cancer cells often use clever signals to hide from the body's natural defences. Evorpacept is designed to block one of these 'don't eat me' signals, helping the immune system to find and destroy cancer cells. In this study, evorpacept is given alongside existing treatments, including Herceptin (trastuzumab), Cyramza (ramucirumab), and a chemotherapy medicine called paclitaxel.

By comparing this combination to standard treatments, researchers hope to find out whether adding evorpacept helps shrink tumours, stops the cancer from growing for longer, and improves survival. Finding new, effective combinations is vital for giving people with advanced stomach cancer more treatment options and a better quality of life.

Key takeaways

  • Tests a new immune-boosting drug, evorpacept, for advanced stomach cancer.
  • Specifically for cancers with high levels of the HER2 protein.
  • Combines the trial drug with standard treatments including Herceptin and chemotherapy.
  • All study treatments are given as drips into a vein at the hospital.
  • Participation is voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is for adults aged 18 and over who have been diagnosed with advanced adenocarcinoma of the stomach or the gastro-oesophageal junction. 'Advanced' means the cancer may have spread to nearby tissues or to other parts of the body.

To be considered, tests on your tumour must show that it has high levels of the HER2 protein (known as HER2-positive or HER2-overexpressing). You will also need to have received previous cancer treatment that is no longer controlling the disease, and you must be well enough to carry out everyday activities independently.

You may not be able to take part if you have certain other medical conditions, severe heart problems, active infections, or if you have previously had severe reactions to any of the study medications. A doctor will carry out detailed health checks and blood tests to confirm whether this trial is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or over.
  2. I have advanced cancer of the stomach or where the stomach joins the food pipe.
  3. My cancer has tested positive for high levels of the HER2 protein.
  4. My cancer has grown or returned after previous treatments.
  5. I am well enough to attend regular hospital appointments for infusions and scans.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves regular visits to a hospital clinic. All the study medicines, including evorpacept, Herceptin, Cyramza, and paclitaxel, are given as drips (infusions) directly into a vein. Depending on the group you are placed in, you will attend the clinic on set days every few weeks to receive your treatment.

During your visits, the medical team will carry out health checks. These include physical examinations, blood tests, heart checks (such as ECGs or heart scans), and regular CT or MRI scans to see how your tumour is responding to the treatment. You will also be asked about how you are feeling and whether you have noticed any side effects.

You will continue receiving treatment for as long as it helps keep your cancer under control and the side effects remain manageable. After you stop taking the study medication, the team will continue to check on your health and well-being through routine follow-up appointments or phone calls.

Potential risks and benefits

Taking part may help shrink your tumour or slow down the cancer, but there is no guarantee of direct benefit. The trial will also help doctors learn more about treating stomach cancer in the future. However, all cancer treatments carry risks. You may experience side effects from the chemotherapy and targeted drugs, such as tiredness, sickness, hair loss, low blood cell counts, an increased risk of infection, or infusion reactions. Evorpacept may also cause immune-related side effects. Your care team will monitor you closely to manage any symptoms quickly. Joining the trial is entirely voluntary, and you can withdraw at any time without it affecting your standard NHS care.

Locations (5)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Belgium
  • —
    Unverified
    Spain
  • —
    Unverified
    Italy
  • —
    Unverified
    Czechia
  • —
    Unverified
    France

Common questions

What is HER2-positive stomach cancer?

It means your cancer cells have higher than normal amounts of a protein called HER2 on their surface, which can make the cancer grow faster. Doctors can test a sample of your tumour to see if it is HER2-positive.

How is the trial drug given?

All the study medications, including the trial drug evorpacept, are given through a drip (infusion) into a vein at the hospital.

Will I definitely receive the new drug?

Not necessarily. In clinical trials like this, participants may be randomly assigned to receive either the new drug combination or the current standard treatment, so researchers can compare the results fairly.

Do I have to pay to take part?

No, all study drugs and extra trial-related tests are provided free of charge. Some trials may also help cover travel expenses to and from the hospital.

Can I leave the study if I change my mind?

Yes. You have the right to leave the study at any time, for any reason. Your regular doctors will continue to provide you with the best available standard care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-O…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.